BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

InfaCare Pharmaceutical Corporation Appoints Dr. Simon Tulloch, Chief Medical Officer


6/27/2006 2:47:48 PM

PLYMOUTH MEETING, Pa., June 27 /PRNewswire/ -- InfaCare Pharmaceutical, a privately held, pediatric-focused specialty pharmaceutical company, announced today the appointment of Simon Tulloch, M.D. as Chief Medical Officer. Dr. Tulloch joins InfaCare from Shire Pharmaceutical, where he was Senior VP and Head of US Research and Development and, subsequently, Team Leader of the CNS Global Business Group. Dr. Tulloch trained in medicine at the University of Oxford in the UK, and has worked in drug development in many therapeutic areas in Europe and the USA. He will lead InfaCare's drug development effort and will be a member of the management team.

"We are pleased to welcome Simon to the InfaCare team, especially at a crucial point where the firm can capitalize on the breadth of his drug development expertise," said John Post, CEO of InfaCare. "His experience with managing a broad portfolio of development candidates, coupled with his outstanding track record of successfully achieving regulatory approvals, brings significant experience and insight to the company at an important stage of our development."

"InfaCare is at a really exciting and critical point with its lead drug, Stanate(R), for treating hyperbilirubinemia in neonates. It has tremendous potential clinical benefits in a serious condition, and we are at the point of designing the key studies in collaboration with regulatory agencies that will hopefully lead to an NDA. The caliber of the board and investors is testimony to that potential," said Dr. Tulloch.

About InfaCare Pharmaceutical Corporation:

InfaCare Pharmaceutical Corporation is an emerging specialty pharmaceutical company focused on the acquisition, development and commercialization of products for neonates and older children and is led by John Post, President and CEO. The company was founded in 2001 by Dr. Robert Vukovich (Chairman of InfaCare), formerly the founder and CEO/Chairman of Roberts Pharmaceutical Corporation prior to its sale to Shire Pharmaceutical Group in 1999. InfaCare is financed by leading venture capital investors and is headquartered in Plymouth Meeting, Pennsylvania.

For more information please visit our website (http://www.infacarepharm.com) or contact Ron Goldfuss, Chief Financial Officer, InfaCare Pharmaceutical at 610-260-1485 rgoldfuss@infacarepharm.com.

InfaCare Pharmaceutical Corporation

CONTACT: Ron Goldfuss, Chief Financial Officer, InfaCare Pharmaceutical,+1-610-260-1485, rgoldfuss@infacarepharm.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES